


Express Mail Label No.: EV 460337745 US
Date of Deposit: March 30, 2006

Attorney Docket No.: 26448-510 CON



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Egan, et al.

SERIAL NUMBER : 10/037,447

EXAMINER : Cybille Delacroix-Muirheid

FILING DATE : December 31, 2001

ART UNIT : 1614

FOR : METHOD FOR TREATING FIBROTIC DISEASES OR OTHER
INDICATIONS ID

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER


Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1page), in duplicate; and
3. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 26448-510 CON. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

 Reg No. 50,572

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Customer No. 30623

Date: March 30, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Egan et al.

SERIAL NUMBER : 10/037,447

EXAMINER : Cybille Delacroix-Muirheid

FILING DATE : December 31, 2001

ART UNIT : 1614

FOR : METHOD FOR TREATING FIBROTIC DISEASES OR OTHER
INDICATIONS ID

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant hereby makes of record the documents listed on the attached modified Form PTO-1449.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the Supplementary European Search Report for EP 01 95 8946, mailed February 8, 2006. Accordingly, no fee or certification is believed required. Copies of the references are not provided as they were previously cited and/or submitted to the USPTO in prior application: Serial No. 09/905,188, filed July 13, 2001 and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.



APPLICANTS: Egan et al.
U.S.S.N.: 10/037,447

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 26448-510 CON.

Respectfully submitted,

 Reg No. 50,572

Ivor R. Elrifi, Reg. No. 39,529

Attorney(s) for Applicants
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: March 30, 2006

TRA 2136490v.1

Express Mail No.: EV 460337745 US
Date of Deposit: March 30, 2006



Page 1 of 1
Attorney Docket No.: 26448-510 CON

Please type a plus sign (+) in this box

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/037,447
	Filing Date	December 31, 2001
	First Named Inventor	Egan
	Group Art Unit	1614
	Examiner Name	Cybillie Delacroix-Muirheid
	Attorney Docket Number	26448-510 CON

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	*B3	WO	96/22095	ALTEON INC.; THE PICOWER INSTITUTE FOR MEDICAL RESEARCH	07/25/96		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C2	Asif et al. <i>PNAS</i> , 97(6):2809-2813 (2000)
	*C3	Lee et al. <i>J. Am. Soc. Nephrol.</i> , Abstract only, 9:641A (1997)
	*C4	Rossert et al. <i>Diabetes Metab.</i> , 26(4):16-24 (2000)
	*C5	Sakata et al. <i>J. Atheroscler. Thromb.</i> , 7(3):169-176 (2000)
	*C6	Twigg et al. <i>Endocrinol.</i> , 142(5):1760-1769 (2001)
	*C7	Wolffenbittel et al. <i>Proc. Natl. Acad. Sci. USA</i> , 95(8):4630-4634 (1998)
	*C8	Supplementary European Search Report for EP 01 95 8946, mailed February 8, 2006.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/905,188, filed 07/13/2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.